Israel spends only 7.6% of the GDP on healthcare – significantly less than most other Western OECD countries. At the same time Israel has a higher life expectancy and lower infant mortality. So, better results for less money?! How does… Continue Reading
The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered… Continue Reading
Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when… Continue Reading
The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system. The two experts on the Austrian market, Dr. Stefan Walzer and Dr. Anna Bucsics, discuss about the pathways in Asutria but also… Continue Reading
The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow, access and commercialization, especially of new and innovative therapies could firstly be introduced through the private system.… Continue Reading
